Menopause HRT — Guidelines vs. Evidence
Society guidance on hormone therapy risks compared to WHI-era and modern route-specific evidence.
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
RAGMD evidence position
Transdermal estrogen carries lower VTE risk than oral estrogen; HRT timing and route matter for risk-benefit.
Guideline vs. evidence
| Guideline | Society position | RAGMD evidence |
|---|---|---|
| NAMS (2022) | Supports individualized HRT for symptomatic women under 60 or within 10 years of menopause onset when benefits outweigh risks. | Evidence supports route-specific VTE risk (oral > transdermal) and timing-window considerations from WHI subgroup analyses.Open evidence analysis → |
| AHA | Does not recommend HRT for cardiovascular protection; emphasizes CV risk factor management. | WHI and subsequent analyses show timing-dependent CV effects — early menopause HRT may differ from late initiation.Open evidence analysis → |
| USPSTF | Recommends against combined estrogen-progestin for chronic disease prevention in postmenopausal women. | RAGMD distinguishes symptomatic treatment decisions from chronic disease prevention — different PICO than USPSTF framing.Open evidence analysis → |
Key studies
- WHI estrogen plus progestin · PMID 12117397
- Oral vs transdermal estrogen VTE · PMID 30626577